CLINICAL TRIALS PROFILE FOR SUSTOL
✉ Email this page to a colleague
All Clinical Trials for sustol
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05434663 ↗ | Phase 4, Open-Label Safety Study of SUSTOL | Recruiting | Heron Therapeutics | Phase 4 | 2022-12-01 | This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOLĀ® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sustol
Condition Name
Clinical Trial Locations for sustol
Trials by Country
Clinical Trial Progress for sustol
Clinical Trial Phase
Clinical Trial Sponsors for sustol
Sponsor Name